Skip to Content
Merck
CN
  • Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice.

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice.

Cell host & microbe (2019-11-02)
Rafael A Larocca, Erica A Mendes, Peter Abbink, Rebecca L Peterson, Amanda J Martinot, Mark Justin Iampietro, Zi H Kang, Malika Aid, Marinela Kirilova, Catherine Jacob-Dolan, Lisa Tostanoski, Erica N Borducchi, Rafael A De La Barrera, Dan H Barouch
ABSTRACT

Maternal infection with Zika virus (ZIKV) can lead to microcephaly and other congenital abnormalities of the fetus. Although ZIKV vaccines that prevent or reduce viremia in non-pregnant mice have been described, a maternal vaccine that provides complete fetal protection would be desirable. Here, we show that adenovirus (Ad) vector-based ZIKV vaccines induce potent neutralizing antibodies that confer robust maternal and fetal protection against ZIKV challenge in pregnant, highly susceptible IFN-αβR-/- mice. Moreover, passive transfer of maternal antibodies from vaccinated dams protected pups against post-natal ZIKV challenge. These data suggest that Ad-based ZIKV vaccines may be able to provide protection in pregnant females against fetal ZIKV transmission in utero as well as in infants against ZIKV infection after birth.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Xylenes, histological grade